Oryzon Genomics Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Oryzon Genomics stock has a consensus rating of "Strong Buy" and an average price target of €7.13. The average 1-year stock price forecast is 138.14% higher than the current stock price, while the lowest is €4.20 (+40.28%) and the highest is €12.00 (+300.80%).

Price Target: €7.13 (+138.14%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	€4.20	€7.13	€5.20	€12.00
Change	+40.28%	+138.14%	+73.68%	+300.80%

Analyst Ratings

The average analyst rating for Oryzon Genomics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	3	3	3
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Jefferies No rating	Jefferies	Buy Maintains €4.20	Buy	Maintains	€4.20	+40.28%	May 25, 2026
Jason McCarthy Maxim Group	Maxim Group	Buy Maintains €8.68	Buy	Maintains	€8.68	+189.85%	May 16, 2026

Financial Forecast

Revenue This Year

7.59M

from 12.84M

-40.91%

from 12.84M

Revenue Next Year

19.54M

from 7.59M

157.58%

from 7.59M

EPS This Year

-0.14

from -0.04

EPS Next Year

0.02

from -0.14

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	12.07M	16.78M	15.69M	7.62M	12.84M	7.59M
Revenue Growth	3.66%	38.97%	-6.50%	-51.43%	68.51%	-40.91%
Gross Profit	11.22M	16.28M	15.42M	7.31M	12.51M	7.44M
Gross Margin	92.97%	97.04%	98.28%	95.89%	97.42%	98.05%
Operating Income	-7.98M	-5.87M	-5.04M	-4.66M	-6.71M	-15.52M
Net Income	-5.33M	-4.52M	-3.71M	-3.70M	-3.06M	-11.48M
EPS	-	-	-	-	-0.04	-0.14
Free Cash Flow	-17.89M	-17.29M	-20.58M	-13.54M	-13.93M	-26.30M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	19.4M
Avg	7.6M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	51.4%
Avg	-40.9%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.14
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-